VolitionRx Limited (VNRX)
After hours:
| Previous close | 0.8500 |
| Open | 0.8541 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's range | 0.7800 - 0.8608 |
| 52-week range | 0.5500 - 2.1000 |
| Volume | |
| Avg. volume | 174,732 |
| Market cap | 65.655M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5000 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.73 |
PR NewswireNu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech, a leading veterinary diagnostics company.
Insider MonkeyVolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript
VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript March 26, 2024 VolitionRx Limited isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full […]
PR NewswireVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023. Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.
